Does ATAI Life Sciences’ ‘biotech platform’ provide the antidote to traditional drug discovery model?

Does ATAI Life Sciences' 'biotech platform' provide the antidote to traditional drug discovery model?

Last Updated on

Elon Musk colleague and strong Bitcoin advocate Peter Thiel has backed an interesting platform company looking to disrupt the drug discovery business. TBH, the main focus is on how things in the mental atmosphere impact the brain and mental. Naturally, there is emphasis on the OTP of magic mushrooms and cannabis to see how shrooms can be used to ultimately create easy products for consumers such as CBD Gummies or CBD Salve. Will be interesting to see how this shakes out.

Set up two years ago, it has attracted more than US$100mln in Series A and B funding that has brought in an impressive roster of early investors, including Peter Thiel, the co-founder of both PayPal and Palantir It’s hard not to associate the word psychedelic with the trippy, tie-dyed […]

Click here to view original web page at www.proactiveinvestors.co.uk

Leave a Reply

Your email address will not be published. Required fields are marked *